Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.

Ji Eun WonYoungseon ByeonTae In WiChan Mi LeeJu Hyeong LeeTae Heung KangJeong-Won LeeYoungJoo LeeYeong-Min ParkHee Dong Han

Published in: Journal for immunotherapy of cancer (2022)

Our findings suggest a potential combination approach for cancer immunotherapy using PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs and PLGA (antigen+adjuvant)-NPs as novel immune checkpoint silencing agents.

Keyphrases

drug delivery
cancer therapy
drug release
early stage
bone regeneration
oxide nanoparticles
hyaluronic acid
human health
risk assessment
climate change
walled carbon nanotubes